Anti-endothelin drugs in solid tumors

Expert Opinion on Emerging Drugs
Antonio RussoViviana Bazan

Abstract

The endothelin (ET) axis, which includes the biological functions of ETs and their receptors, has played a physiological role in normal tissue, acting as a modulator of vasomotor tone, tissue differentiation and development, cell proliferation and hormone production. Interestingly, it also functions in the growth and progression of various tumors. Several researchers have identified the blockade of the ET-1 receptor as a promising therapeutic approach. The clinical investigation of an orally bioavailable ET antagonist, atrasentan, in prostate cancer, is encouraging. In this neoplasia, it has shown antitumor activity, bone metastasis control and amelioration of cancer-related pain but improvement in time to progression and overall survival has still not been demonstrated. The clinical trials of other ET antagonists are reported. Literature research was performed by Pubmed and Pharmaprojects. A comprehensive view about the use of atrasentan in the treatment of castration-resistant prostate cancer (CRPC) is provided together with the scientific rationale based on the function of ET and its receptor in various cancer development mechanisms. Atrasentan seems to be active in CRPC, although strong scientific evidence is still to be fo...Continue Reading

References

Jul 31, 1992·Biochemical and Biophysical Research Communications·M ClozelR Osterwalder
Jan 1, 1991·Journal of Cardiovascular Pharmacology·M ShichiriF Marumo
Jan 1, 1991·Life Sciences·R B RaffaH I Jacoby
Jan 1, 1989·Journal of Cardiovascular Pharmacology·Y Hirata
Jan 1, 1989·Journal of Cardiovascular Pharmacology·S H FerreiraG de Nucci
Jan 1, 1989·Journal of Cardiovascular Pharmacology·M S SimonsonM J Dunn
Apr 1, 1989·Japanese Journal of Cancer Research : Gann·M KusuharaY Nakamura
May 1, 1989·The Journal of Clinical Investigation·M ClozelC Guilly
Sep 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·M YanagisawaK Goto
Aug 10, 1995·The New England Journal of Medicine·E R Levin
Mar 1, 1993·Peptides·B BattistiniP Sirois
Jul 10, 1997·Nature·M IrmlerJ Tschopp
Jun 20, 1998·The Journal of Biological Chemistry·M OkazawaT Masaki
Sep 29, 1999·Proceedings of the National Academy of Sciences of the United States of America·R LahavP H Patterson
Sep 8, 2000·Journal of Cardiovascular Pharmacology·T Masaki
Sep 23, 2000·Nature·P Carmeliet, R K Jain
Oct 29, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·A VenutiA Bagnato
Nov 14, 2000·The American Journal of Pathology·D SalaniA Bagnato
Nov 15, 2000·Journal of Cardiovascular Pharmacology·H AliI Taylor
Nov 25, 2000·Laboratory Investigation; a Journal of Technical Methods and Pathology·G EgidyL Juillerat-Jeanneret
Mar 10, 2001·The American Journal of Pathology·A BagnatoP G Natali
Apr 18, 2001·Journal of Clinical Pharmacology·E SamaraR J Padley
Jan 10, 2002·Nature·R CorderM J Carrier
Mar 14, 2002·The American Journal of Pathology·Carsten DenkertSteffen Hauptmann
Jun 12, 2002·Canadian Journal of Physiology and Pharmacology·Arco Y JengBruno Battistini
Aug 16, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G FerrandinaG Scambia
Dec 4, 2002·Nature Reviews. Drug Discovery·Giuseppe RemuzziAriela Benigni
Jan 28, 2003·Cancer·Theresa A GuiseKhalid S Mohammad
Feb 4, 2003·Nature Reviews. Cancer·Joel NelsonPerry Nisen
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael A CarducciJoel B Nelson
Mar 6, 2003·British Journal of Cancer·L Peduto EberlL Juillerat-Jeanneret
Aug 28, 2003·Proceedings of the National Academy of Sciences of the United States of America·Juan Juan YinTheresa A Guise
Sep 16, 2003·Biochimica Et Biophysica Acta·Natasha FosterKeith K Stanley
Jan 7, 2004·Cancer Cell·Andrew J Dannenberg, Kotha Subbaramaiah
Apr 6, 2004·Trends in Pharmacological Sciences·Tomoh Masaki
May 29, 2004·Journal of Translational Medicine·Anna Bagnato, Pier Giorgio Natali
Jan 18, 2005·World Journal of Urology·Joel B Nelson
Mar 10, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hiroaki KajiyamaFumitaka Kikkawa

❮ Previous
Next ❯

Citations

May 21, 2010·Drugs·Giuseppe Di LorenzoCora N Sternberg
Dec 24, 2011·Expert Review of Anticancer Therapy·Jean-Jacques Body
Aug 24, 2010·Regulatory Peptides·Renata R HoffmannMaria M Campos
Mar 3, 2011·International Journal of Cancer. Journal International Du Cancer·Jung-Kang JinGary E Gallick
Jan 4, 2012·Journal of Surgical Oncology·Paraskevi LiakouGeorge Z Rassidakis
Feb 6, 2021·Critical Reviews in Oncology/hematology·Girolamo MannoGiuseppina Novo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

International Journal of Cancer. Journal International Du Cancer
Shuji AwanoBadar A Usmani
European Journal of Clinical Investigation
A BhallaM Loizidou
The International Journal of Biochemistry & Cell Biology
Anna Bagnato, Laura Rosanò
© 2021 Meta ULC. All rights reserved